We have created a portfolio of novel neuropeptides that are in various stages of development and pre-clinical evaluation for the treatment of stress-related disorders. The lead product candidate, PT00114, is targeted to treat PTSD and Drug & Alcohol Addiction without interfering with normal brain function.
Over 15 years of accumulated research, Protagenic Therapeutics’ scientists are discovering the actions of a family of neuropeptides called TCAPs, from the genetic level through systemic biological changes that impact physiology and behavior.
The potential to improve mental health by counterbalancing stress overdrive and restoring the health of neuronal cells represents an exciting paradigm shift in treatment approaches.
Leveraging activity impacting multiple neuropathological processes, Protagenic is reaching beyond the boundaries of traditional therapeutics for stress-related disorders, by focusing on restoring the body’s natural equilibrium.
Amino acids in length
Million years of molecular conservation
Major human disease targets
Years of Development at Protagenic Therapeutics, Inc.